Task Group 174 Report: Utilization of [ 18 F]Fluorodeoxyglucose Positron Emission Tomography ([ 18 F]FDG-PET) in Radiation Therapy.

Autor: Das SK; Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA., McGurk R; Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA., Miften M; Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA., Mutic S; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA., Bowsher J; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA., Bayouth J; Human Oncology, University of Wisconsin, Madison, WI, USA., Erdi Y; Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Mawlawi O; Department of Imaging Physics, University of Texas, M D Anderson Cancer Center, Houston, TX, USA., Boellaard R; Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands., Bowen SR; Department of Radiation Oncology, University of Washington, Seattle, WA, USA., Xing L; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA., Bradley J; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA., Schoder H; Molecular Imaging and Therapy Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Yin FF; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA., Sullivan DC; Department of Radiology, Duke University School of Medicine, Durham, NC, USA., Kinahan P; Department of Radiology, University of Washington, Seattle, WA, USA.
Jazyk: angličtina
Zdroj: Medical physics [Med Phys] 2019 Oct; Vol. 46 (10), pp. e706-e725. Date of Electronic Publication: 2019 Sep 06.
DOI: 10.1002/mp.13676
Abstrakt: The use of positron emission tomography (PET) in radiation therapy (RT) is rapidly increasing in the areas of staging, segmentation, treatment planning, and response assessment. The most common radiotracer is 18 F-fluorodeoxyglucose ([ 18 F]FDG), a glucose analog with demonstrated efficacy in cancer diagnosis and staging. However, diagnosis and RT planning are different endeavors with unique requirements, and very little literature is available for guiding physicists and clinicians in the utilization of [ 18 F]FDG-PET in RT. The two goals of this report are to educate and provide recommendations. The report provides background and education on current PET imaging systems, PET tracers, intensity quantification, and current utilization in RT (staging, segmentation, image registration, treatment planning, and therapy response assessment). Recommendations are provided on acceptance testing, annual and monthly quality assurance, scanning protocols to ensure consistency between interpatient scans and intrapatient longitudinal scans, reporting of patient and scan parameters in literature, requirements for incorporation of [ 18 F]FDG-PET in treatment planning systems, and image registration. The recommendations provided here are minimum requirements and are not meant to cover all aspects of the use of [ 18 F]FDG-PET for RT.
(© 2019 American Association of Physicists in Medicine.)
Databáze: MEDLINE
Externí odkaz: